Marcio Souza, Praxis Precision Medicines CEO

Prax­is prices $150M pub­lic stock of­fer­ing ahead of four topline neu­ro read­outs in 2024

Boston-based Prax­is Pre­ci­sion Med­i­cines an­nounced Thurs­day the pric­ing of a $150 mil­lion pub­lic stock of­fer­ing, with an ex­pect­ed close date around …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.